To include your compound in the COVID-19 Resource Center, submit it here.
Sanofi received rights to develop and commercialize Glenmark's autoimmune candidate GBR 500. The mAb against integrin
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury